In addition, some found that the ≥2% cut-off for JAK2 V617F allele burden was of clinical interest as such patients were more likely to present with splenomegaly and evolve towards MPN within first year of follow up [27]. This evidence concerns the gene JAK2 and myeloproliferative neoplasm.